Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients
- PMID: 11301402
Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients
Abstract
Background: Positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) is a rapidly developing new imaging technique in the diagnosis and staging of melanoma. The objective of the current study was to determine the diagnostic accuracy of FDG-PET in patients with melanoma.
Methods: A systematic review and meta-analysis of clinical studies regarding FDG-PET and cutaneous melanoma was conducted. Studies were identified by a comprehensive search of the MEDLINE, EMBASE, and Current Contents databases, without any language restrictions. Eleven studies were selected. The methodologic quality of these studies was assessed independently by two reviewers. Levels of evidence and grades of recommendation were determined for each study. Six studies could be included in the statistical pooling. Sources of heterogeneity were studied by meta-regression of the diagnostic odds ratio (DOR). A summary receiver operating characteristic curve was calculated.
Results: The pooled sensitivity and specificity of FDG-PET in the detection of melanoma metastases were 0.79 (95% confidence interval [95% CI], 0.66-0.93) and 0.86 (95% CI, 0.78-0.95), respectively. The pooled DOR of 33.1 (95% CI, 21.9-54.0) suggests a high diagnostic accuracy for PET. Subgroup analysis revealed that PET is more accurate for systemic staging (DOR of 36.4) than for regional staging (DOR of 19.5). When used for regional staging, PET performed better in patients with American Joint Committee on Cancer Stage III disease, compared with patients with Stage I and Stage II disease. However, the methodologic quality of the studies was limited. Major problems were verification, review, and selection bias.
Conclusions: Due to the poor methodologic quality of the available studies, to the authors' knowledge it is yet not possible to develop guidelines for the effective use of PET in patients with melanoma. Future accuracy studies should meet the methodologic criteria outlined in the current review.
Copyright 2001 American Cancer Society.
Similar articles
-
Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma.Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):284-300. doi: 10.1007/s00259-009-1224-8. Epub 2009 Sep 2. Eur J Nucl Med Mol Imaging. 2010. PMID: 19727717 Free PMC article.
-
Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.Cancer. 2005 Aug 1;104(3):570-9. doi: 10.1002/cncr.21189. Cancer. 2005. PMID: 15977211
-
Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.Eur J Radiol. 2018 Oct;107:158-165. doi: 10.1016/j.ejrad.2018.09.003. Epub 2018 Sep 5. Eur J Radiol. 2018. PMID: 30292261
-
Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.Oncology. 2019;97(5):286-293. doi: 10.1159/000501398. Epub 2019 Aug 22. Oncology. 2019. PMID: 31437839
-
A review of the literature for whole-body FDG PET in the management of patients with melanoma.Q J Nucl Med. 2000 Jun;44(2):153-67. Q J Nucl Med. 2000. PMID: 10967625
Cited by
-
A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.Ann Surg. 2012 Aug;256(2):350-6. doi: 10.1097/SLA.0b013e318256d1f5. Ann Surg. 2012. PMID: 22691370 Free PMC article.
-
The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296. doi: 10.1007/s00259-018-3972-9. Epub 2018 Feb 24. Eur J Nucl Med Mol Imaging. 2018. PMID: 29478079 Clinical Trial.
-
Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.Cochrane Database Syst Rev. 2019 Jul 1;7(7):CD012806. doi: 10.1002/14651858.CD012806.pub2. Cochrane Database Syst Rev. 2019. PMID: 31260100 Free PMC article.
-
F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.Syst Rev. 2012 Dec 13;1:62. doi: 10.1186/2046-4053-1-62. Syst Rev. 2012. PMID: 23237499 Free PMC article.
-
Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab.EJNMMI Res. 2016 Dec;6(1):61. doi: 10.1186/s13550-016-0216-5. Epub 2016 Jul 29. EJNMMI Res. 2016. PMID: 27473846 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical